Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · West Pharmaceutical Services (WST)

West Pharmaceutical names Robert McMahon CFO, effective August 4, 2025

Neutral Impact 4 of 5 leadership Written later

West Pharmaceutical Services appointed Robert McMahon, formerly CFO of Agilent Technologies, as Senior Vice President and Chief Financial Officer effective August 4, 2025, succeeding Bernard Birkett, who is retiring and will serve as Senior Advisor to the CEO through December 31, 2025. The filing discloses pay terms including an $800,000 base salary, a $3,115,000 sign-on bonus and a $4,200,000 replacement equity grant, which matter to shareholders as a change in the company's top finance role and a related compensation cost.

Key points

  • Robert McMahon becomes SVP and CFO effective August 4, 2025, overseeing finance, audit, treasury, tax, investor relations and procurement.
  • Offer terms include an $800,000 initial base salary and an annual bonus target of 80% of base salary.
  • One-time cash sign-on bonus of $3,115,000 and a replacement equity grant with a grant date fair value of $4,200,000.
  • LTI award with grant date fair value of $3,000,000 is scheduled for August 11, 2025.

The filing

CompanyWest Pharmaceutical Services (WST)
Form8-K, current report
Filed with the SECJul 21, 2025, 4:17 PM ET
Accession number0000105770-25-000058

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 21, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.